CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
Authors
Keywords
-
Journal
Cancers
Volume 10, Issue 9, Pages 323
Publisher
MDPI AG
Online
2018-09-11
DOI
10.3390/cancers10090323
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
- (2018) Wolfgang Willenbacher et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
- (2017) Arnab Ghosh et al. LEUKEMIA & LYMPHOMA
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Novel Immunotherapies for Multiple Myeloma
- (2017) Mattia D’Agostino et al. Current Hematologic Malignancy Reports
- A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
- (2017) Dina Schneider et al. Journal for ImmunoTherapy of Cancer
- CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth
- (2017) Vita Golubovskaya et al. Cancers
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Immunotherapy and tumor microenvironment
- (2016) Haidong Tang et al. CANCER LETTERS
- Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
- (2016) Kole T. Roybal et al. CELL
- The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing
- (2016) Liren Qian et al. CELLULAR IMMUNOLOGY
- Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
- (2016) Eugene A Zhukovsky et al. CURRENT OPINION IN IMMUNOLOGY
- A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
- (2016) S Hipp et al. LEUKEMIA
- Anti-BCMA CAR T cells show promise in MM
- (2016) Peter Sidaway Nature Reviews Clinical Oncology
- Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells
- (2016) Na An et al. Oncotarget
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
- (2016) E. Zah et al. Cancer Immunology Research
- Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
- (2016) Vita Golubovskaya et al. Cancers
- Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis
- (2015) Tengfei Zhang et al. Oncotarget
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
- (2013) J. N. Kochenderfer et al. BLOOD
- Zoom Zoom: Racing CARs for Multiple Myeloma
- (2013) M. V. Maus et al. CLINICAL CANCER RESEARCH
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- APRIL Binding to BCMA Activates a JNK2-FOXO3-GADD45 Pathway and Induces a G2/M Cell Growth Arrest in Liver Cells
- (2012) G. Notas et al. JOURNAL OF IMMUNOLOGY
- Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies
- (2010) J. K. Davies et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started